SCRMP-mediated SUMOylation of CSNK2B facilitates DNA damage repair to promote cisplatin resistance in small cell lung cancer.

SCRMP-mediated SUMOylation of CSNK2B enhances DNA repair, driving cisplatin resistance in small cell lung cancer with a 128-amino acid protein involved.

• Why it matters: Understanding platinum resistance mechanisms in SCLC is critical, as it leads to treatment failure and poor patient outcomes, yet remains poorly characterized.
• What they did: Researchers used multiomic analysis and CRISPR-Cas9 gene editing to identify and study SCRMP, a noncanonical protein upregulated in resistant tissues, and examined its role in DNA repair pathways.
• The result: SCRMP promotes resistance by facilitating CSNK2B SUMOylation and nuclear translocation, activating DNA repair genes, and suggesting new targets for overcoming platinum resistance in SCLC.